May 4, 2017

Refocus Group Concludes 12-Month Follow-Up for Phase 3 Clinical Trial on the VisAbility™ Micro-Insert System for Presbyopia; Readies for Pre-Market Approval Submission

October 21, 2016

VisAbility™ Micro-insert System presented at this year’s American Academy of Ophthalmology meeting in Chicago. An audience of over 500+ ophthalmic surgeons receive an update presented by James Katz, MD with respect to the evolution, safety & efficacy of this micro-solution for presbyopia reversal.

June 2, 2016

UPDATE: VISABILITY INSERT SYSTEM GENERATES WIDESPREAD PRESS COVERAGE AT THE 2016 OIS/ASCRS ANNUAL MEETING

May 5, 2016

Press Release: Refocus Group Completes Phase 3 Clinical Trial on the VisAbility™ Micro-Insert System for Presbyopia

Refocus Group just completed enrollment for its Phase 3 clinical trial on the VisAbility™ Micro-Insert System for presbyopia, with 360 subjects between the ages of 45 and 60 at 13 clinical sites in the US. The company has also secured an additional $15 million in new financing from MedCare Investment Funds and WP Global Partners.